KYSE-410 Xenograft Model Service for Esophageal Squamous Cell Carcinoma (ESCC)

The KYSE-410 xenograft model offers a robust and clinically relevant platform for preclinical evaluation of novel therapeutic strategies against esophageal squamous cell carcinoma, faithfully recapitulating the histopathological and molecular features of human ESCC in an immunodeficient host environment. Alfa Cytology delivers a fully validated KYSE-410 xenograft service built on standardized tumor implantation protocols, rigorous in-life monitoring, and comprehensive endpoint analysis to accelerate your preclinical drug development pipeline with reproducible, high-quality data.

Overview of KYSE-410 Xenograft Model for Esophageal Squamous Cell Carcinoma (ESCC)

KYSE-410 is a human esophageal squamous cell carcinoma (ESCC) cell line originally established from a poorly differentiated invasive primary tumor resected from the cervical esophagus of a 51-year-old male patient prior to treatment. As a member of the extensively characterized KYSE series, this cell line exhibits epithelial morphology with adherent monolayer growth and a doubling time of approximately 24-45 hours under standard culture conditions. Genetically, KYSE-410 is distinguished by epigenetic silencing of the p16 (INK4a) tumor suppressor gene via hypermethylation of its 5' CpG islands, while retaining wild-type p15 (INK4b), a selective inactivation pattern frequently observed in ESCC subtypes. The cell line also demonstrates overexpression of heparin-binding growth factor (hst-1) and cyclin D1, contributing to its proliferative drive. Its confirmed tumorigenicity in athymic nude mice, with resultant tumors displaying classical squamous cell carcinoma histology, makes KYSE-410 a cornerstone model for investigating ESCC biology and therapeutic intervention.

In the preclinical setting, the KYSE-410 xenograft model serves as a predictive platform for evaluating cytotoxic agents, targeted therapies, and epigenetic modulators. The model has been successfully employed in studies assessing platinum-based compounds, miRNA-targeted interventions, and agents modulating apoptosis via caspase-dependent pathways. Tumors derived from KYSE-410 maintain molecular fidelity to the parental cell line, enabling researchers to correlate in vivo efficacy with mechanistic endpoints such as cell cycle dysregulation, apoptotic induction, and anti-proliferative response. This makes the model particularly valuable for translational studies bridging in vitro findings to in vivo pharmacodynamics.

Figure 1. Cell proliferation, EGFR expression, gel electrophoresis, and immunofluorescent staining of esophageal squamous cell carcinoma cells. (Miyake, Takanori, et al., 2026)

Cell Line Information: KYSE-410

The following table summarizes the essential characteristics and culture parameters of the KYSE-410 cell line:

Our Services

Alfa Cytology provides a comprehensive, end-to-end KYSE-410 xenograft model service tailored to your preclinical research objectives. From cell line authentication and expansion under stringent quality control to standardized subcutaneous or orthotopic implantation, longitudinal tumor monitoring, and multi-parameter endpoint analysis, our platform ensures reproducible tumor growth kinetics and pharmacologically meaningful readouts. Whether your program requires single-agent efficacy studies, combination therapy assessments, or biomarker-driven mechanistic investigations, our experienced team delivers customized study designs with rigorous data integrity and rapid turnaround times.

Workflow of KYSE-410 Xenograft Model Construction

The construction of the KYSE-410 xenograft model follows a systematic, quality-controlled workflow encompassing cell preparation, animal implantation, in-life monitoring, and terminal analysis. Each phase is designed to ensure tumor engraftment consistency, animal welfare compliance, and generation of robust preclinical data.

1. Cell Line Authentication and Expansion: KYSE-410 cells are revived from cryopreserved stocks and authenticated via short tandem repeat (STR) profiling to confirm identity. Cells are expanded in RPMI 1640 supplemented with 10% FBS under standard incubation conditions, with regular mycoplasma and viability monitoring to ensure high-quality inoculum.
2. Pre-Implantation Cell Preparation: Exponentially growing cells are harvested using trypsin/EDTA, washed with sterile PBS, and resuspended in a serum-free medium or Matrigel/medium mixture at an optimized concentration (typically 1-5 x 10^6 cells per 100-200 microL) to enhance engraftment efficiency.
3. Animal Preparation and Implantation: Immunodeficient mice (athymic nude or NOD-SCID) are acclimatized under pathogen-free conditions. KYSE-410 cell suspension is implanted subcutaneously into the flank or orthotopically into the esophageal wall, depending on study objectives, using aseptic surgical techniques.
4. Tumor Growth Monitoring: Tumor dimensions are measured twice weekly using digital calipers, and volumes are calculated via the modified ellipsoid formula (length x width^2 x 0.5). Body weight and general health status are recorded concurrently to assess treatment tolerability.
5. Treatment Administration: Upon reaching a predetermined tumor volume (typically 100-200 mm^3), animals are randomized into treatment and vehicle control groups. Test articles are administered according to the study protocol (e.g., intraperitoneal, intravenous, or oral gavage) with dosing schedules optimized for pharmacokinetic exposure.
6. Endpoint Analysis and Data Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E staining), immunohistochemistry (Ki-67, cleaved caspase-3), and molecular profiling (Western blot, qPCR). Blood samples may be collected for pharmacokinetic or biomarker analysis.

Figure 2: Schematic workflow illustrating the derivation and construction of the KYSE-410 Xenograft Model at Alfa Cytology.

Case Study-KYSE-410 Xenograft Model Development

In a representative preclinical engagement, KYSE-410 xenografts were established in athymic nude mice to evaluate the anti-tumor efficacy of a novel therapeutic candidate. Following subcutaneous implantation, tumors achieved measurable volumes within 10-14 days and demonstrated consistent growth kinetics across the cohort. Treatment initiation at a mean tumor volume of 150 mm^3 resulted in dose-dependent tumor growth inhibition, with the high-dose group exhibiting significant reduction in terminal tumor weight compared to vehicle controls. Histological analysis revealed decreased Ki-67 proliferation index and increased apoptotic bodies in treated tumors, corroborating the pharmacodynamic mechanism. This case exemplifies the utility of the KYSE-410 model in generating translational data to support candidate selection and IND-enabling studies.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific expertise with operational excellence to deliver KYSE-410 xenograft studies that meet the highest standards of preclinical research. Our integrated platform is designed to advance your therapeutic programs with speed, precision, and regulatory confidence.

• Fully validated KYSE-410 cell stocks with STR authentication, mycoplasma clearance, and documented tumorigenicity in immunodeficient mice.
• Standardized xenograft protocols with optimized implantation techniques ensuring high engraftment rates and reproducible tumor growth curves.
• Comprehensive in-life monitoring including twice-weekly tumor caliper measurements, body weight tracking, and clinical observation by trained veterinary staff.
• Multi-modal endpoint analysis encompassing tumor biometrics, histopathology, immunohistochemistry, and molecular biomarker quantification.
• Flexible study designs accommodating single-agent, combination, dose-escalation, and biomarker-driven protocols with customized scheduling.
• Rapid project initiation and streamlined reporting to accelerate your preclinical timeline and support seamless transition to IND-enabling packages.

Contact Us

Ready to advance your esophageal cancer research program with a validated KYSE-410 xenograft model? Please reach out to us today via our inquiry form or email to learn more about our KYSE-410 Xenograft Model services.

For research use only. Not intended for any clinical use.